AbbVie Inc. (ABBV) CEO Discusses Q2 2013 Results - Earnings Call Transcript Seeking Alpha Daclizumab, currently in Phase III development in partnership with Biogen for multiple sclerosis – our second pivotal study will read out next year and we're planning global registration submissions in 2014 as well. Elagolix is being evaluated in Phase ... |
